Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

NCT01290302 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
Myelofibrosis
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia

Interventions

DRUG: Luitpold Azacitidine
DRUG: Vidaza®

Sponsor

American Regent, Inc.